Jeffrey L. Anderson

Jeffrey L. Anderson, MD

Languages spoken: German, English

Academic Information

Departments Primary - Internal Medicine

Divisions: Cardiovascular Medicine

Board Certification

  • American Board of Internal Medicine (Sub: Cardiovascular Disease)
  • American Board of Internal Medicine (Internal Medicine)
  • American Board of Internal Medicine (Sub: Clinical Cardiac Electrophysiology)

Research Statement

Current special interests include the genetics of cardiovascular diseases, biomarkers of coronary disease, advanced cardiovascular imaging (MRI, CTA), pharmacogenetics of cardiovascular disease therapies and adverse reactions, antiarrhythmic drugs, and clinical therapeutic trials.

Education History

Undergraduate University of Utah
 BA
Professional Medical Harvard Medical School
 MD
Residency Massachusetts General Hospital
 Resident
Internship National Institutes of Health
 Research Intern
Fellowship Stanford University Hospital
 Fellow

Selected Publications

Journal Article

  1. Muhlestein JB, May HT, Galenko O, Knowlton KU, Otvos JD, Connelly MA, Lappe DL, Anderson J (2018). GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study. American heart journal, 202, 27-32. (Read full article)
  2. Allen JE, Knight S, McCubrey RO, Bair T, Muhlestein JB, Goldberger JJ, Anderson J (2017). ß-blocker dosage and outcomes after acute coronary syndrome. American heart journal, 184, 26-36. (Read full article)
  3. Huber K, Bates ER, Valgimigli M, Wallentin L, Kristensen SD, Anderson JL, Lopez Sendon JL, Tubaro M, Granger CB, Bode C, Ohman EM, Steg P (2014). Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?. American heart journal, 168(5), 611-21. (Read full article)
  4. Wallentin L, Kristensen SD, Anderson JL, Tubaro M, Sendon JL, Granger CB, Bode C, Huber K, Bates ER, Valgimigli M, Steg PG, Ohman E (2014). How can we optimize the processes of care for acute coronary syndromes to improve outcomes?. American heart journal, 168(5), 622-31. (Read full article)
  5. Kimmel SE, French B, Anderson JL, Gage BF, Johnson JA, Rosenberg YD, Geller NL, Kasner SE, Eby CS, Joo J, Caldwell MD, Goldhaber SZ, Hart RG, Cifelli D, Madigan R, Brensinger CM, Goldberg S, Califf RM, Ellenberg J (2013). Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. American heart journal, 166(3), 435-41. (Read full article)
  6. Anderson JL, Vanwoerkom RC, Horne BD, Bair TL, May HT, Lappé DL, Muhlestein J (2011). Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?. American heart journal, 162(2), 331-339.e2. (Read full article)
  7. Anderson JL, Horne BD, Camp NJ, Muhlestein JB, Hopkins PN, Cannon-Albright LA, Mower CP, Park JJ, Clarke JL, Nicholas ZP, McKinney JT, Carlquist J (2010). Joint effects of common genetic variants from multiple genes and pathways on the risk of premature coronary artery disease. American heart journal, 160(2), 250-256.e3. (Read full article)
  8. May HT, Bair TL, Lappé DL, Anderson JL, Horne BD, Carlquist JF, Muhlestein J (2010). Association of vitamin D levels with incident depression among a general cardiovascular population. American heart journal, 159(6), 1037-43. (Read full article)
  9. Rogers RK, May HT, Anderson JL, Muhlestein J (2009). Prognostic value of B-type natriuretic peptide for cardiovascular events independent of left ventricular end-diastolic pressure. American heart journal, 158(5), 777-83. (Read full article)
  10. May HT, Horne BD, Ronnow BS, Renlund DG, Muhlestein JB, Lappé DL, Pearson RR, Carlquist JF, Kfoury AG, Bair TL, Rasmusson KD, Anderson J (2009). Superior predictive ability for death of a basic metabolic profile risk score. American heart journal, 157(5), 946-54. (Read full article)
  11. Muhlestein JB, Hackett IS, May HT, Bair TL, Le VT, Anderson JL, Whisenant B, Knowlton KU, Lappé D (2019). Safety and Efficacy of Periprocedural Heparin Plus a Short-Term Infusion of Tirofiban Versus Bivalirudin Monotherapy in Patients Who Underwent Percutaneous Coronary Intervention (from the Intermountain Heart Institute STAIR Observational Registry). The American journal of cardiology, 123(12), 1927-1934. (Read full article)
  12. Anderson JL, May HT, Lappé DL, Bair T, Le V, Carlquist JF, Muhlestein J (2016). Impact of Testosterone Replacement Therapy on Myocardial Infarction, Stroke, and Death in Men With Low Testosterone Concentrations in an Integrated Health Care System. The American journal of cardiology, 117(5), 794-9. (Read full article)
  13. Anderson JL, Knight S, May HT, Horne BD, Bair TL, Huntinghouse JA, Rollo JS, Muhlestein JB, Carlquist J (2013). Validation and quantification of genetic determinants of lipoprotein-a levels and predictive value for angiographic coronary artery disease. The American journal of cardiology, 112(6), 799-804. (Read full article)
  14. Burrell LD, Horne BD, Anderson JL, Muhlestein JB, Whisenant B (2013). Usefulness of left atrial appendage volume as a predictor of embolic stroke in patients with atrial fibrillation. The American journal of cardiology, 112(8), 1148-52. (Read full article)
  15. Horne BD, Muhlestein JB, May HT, Carlquist JF, Lappé DL, Bair TL, Anderson JL, Intermountain Heart Collaborative Study Group (2012). Relation of routine, periodic fasting to risk of diabetes mellitus, and coronary artery disease in patients undergoing coronary angiography. The American journal of cardiology, 109(11), 1558-62. (Read full article)
  16. Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, Lappé DL, Muhlestein JB, Intermountain Heart Collaborative (IHC) Study Group (2010). Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. The American journal of cardiology, 106(7), 963-8. (Read full article)
  17. Muhlestein JB, May HT, Bair TL, Prescott MF, Horne BD, White R, Anderson J (2010). Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease. The American journal of cardiology, 106(6), 764-9. (Read full article)
  18. Bunch TJ, Anderson JL, May HT, Muhlestein JB, Horne BD, Crandall BG, Weiss JP, Lappé DL, Osborn JS, Day J (2009). Relation of bisphosphonate therapies and risk of developing atrial fibrillation. The American journal of cardiology, 103(6), 824-8. (Read full article)
  19. Horne BD, May HT, Muhlestein JB, Ronnow BS, Lappé DL, Renlund DG, Kfoury AG, Carlquist JF, Fisher PW, Pearson RR, Bair TL, Anderson J (2009). Exceptional mortality prediction by risk scores from common laboratory tests. The American journal of medicine, 122(6), 550-8. (Read full article)
  20. Rassa AC, Horne BD, McCubrey RO, Bair TL, Muhlestein JB, Morris DR, Anderson J (2015). Novel Stratification of Mortality Risk by Kidney Disease Stage. American journal of nephrology, 42(6), 443-50. (Read full article)
  21. Horne BD, Carlquist JF, Cannon-Albright LA, Muhlestein JB, McKinney JT, Kolek MJ, Clarke JL, Anderson JL, Camp N (2006). High-resolution characterization of linkage disequilibrium structure and selection of tagging single nucleotide polymorphisms: application to the cholesteryl ester transfer protein gene. Annals of human genetics, 70(Pt 4), 524-34. (Read full article)
  22. Horne BD, Hauser ER, Wang L, Muhlestein JB, Anderson JL, Carlquist JF, Shah SH, Kraus W (2009). Validation study of genetic associations with coronary artery disease on chromosome 3q13-21 and potential effect modification by smoking. Annals of human genetics, 73(Pt 6), 551-8. (Read full article)
  23. Shirts BH, Howard MT, Hasstedt SJ, Nanjee MN, Knight S, Carlquist JF, Anderson JL, Hopkins PN, Hunt S (2012). Vitamin D dependent effects of APOA5 polymorphisms on HDL cholesterol. Atherosclerosis, 222(1), 167-74. (Read full article)
  24. Hopkins PN, Nanjee MN, Wu LL, McGinty MG, Brinton EA, Hunt SC, Anderson J (2009). Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study. Atherosclerosis, 207(2), 559-66. (Read full article)
  25. Humphries CM, Anderson JL, Flores JH, Doty J (2013). Cardiac magnetic resonance imaging for perioperative evaluation of sternal eversion for pectus excavatum. European journal of cardio-thoracic surgery, 43(6), 1110-3. (Read full article)
  26. Sarlis NJ, Caticha O, Anderson JL, Kablitz C, Shihab F (1996). Hyperadrenergic state following acute withdrawal from clonidine used at supratherapeutic doses. Clinical autonomic research, 6(2), 115-7. (Read full article)
  27. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buysschaert I, Cardiogenics., Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlini PA, Mooser V, Morgan T, Mühleisen TW, Muhlestein JB, Münzel T, Musunuru K, Nahrstaedt J, Nelson CP, Nöthen MM, Olivieri O, Patel RS, Patterson CC, Peters A, Peyvandi F, Qu L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, Schäfer A, Schillert A, Schreiber S, Schrezenmeir J, Schwartz SM, Siscovick DS, Sivananthan M, Sivapalaratnam S, Smith A, Smith TB, Snoep JD, Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang WH, Tennstedt S, Thorgeirsson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij AM, Voight BF, Wareham NJ, Wells GA, Wichmann HE, Wild PS, Willenborg C, Witteman JC, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien F, Goodall AH, Cupples LA, Quertermous T, März W, Hengstenberg C, Blankenberg S, Ouwehand WH, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts R, Thorsteinsdottir U, O'Donnell CJ, McPherson R, Erdmann J, CARDIoGRAM Consortium., Samani N (2011). Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature genetics, 43(4), 333-8. (Read full article)
  28. Anderson JL, Jacobs V, May HT, Bair TL, Benowitz BA, Lappe DL, Muhlestein JB, Knowlton KU, Bunch T (2019). Free thyroxine within the normal reference range predicts risk of atrial fibrillation. Journal of cardiovascular electrophysiology, 31(1), 18-29. (Read full article)
  29. Mason S, Osborn JS, Dhar R, Tonkin A, Ethington JD, Le V, Benuzillo J, Lappe DL, Knowlton KU, Bunch TJ, Anderson J (2017). Real world MRI experience with nonconditional and conditional cardiac rhythm devices after MagnaSafe. Journal of cardiovascular electrophysiology, 28(12), 1468-1474. (Read full article)
  30. Bunch TJ, May HT, Bair TL, Jacobs V, Crandall BG, Cutler M, Weiss JP, Mallender C, Osborn JS, Anderson JL, Day J (2016). The Impact of Age on 5-Year Outcomes After Atrial Fibrillation Catheter Ablation. Journal of cardiovascular electrophysiology, 27(2), 141-6. (Read full article)
  31. Jacobs V, Woller SC, Stevens SM, May HT, Bair TL, Crandall BG, Cutler M, Day JD, Weiss JP, Osborn JS, Mallender C, Anderson JL, Bunch T (2015). Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Long-Term Risk of Dementia. Journal of cardiovascular electrophysiology, 26(11), 1180-1186. (Read full article)
  32. Bunch TJ, May HT, Bair TL, Jacobs V, Crandall BG, Cutler M, Weiss JP, Mallender C, Osborn JS, Anderson JL, Day J (2015). Five-year outcomes of catheter ablation in patients with atrial fibrillation and left ventricular systolic dysfunction. Journal of cardiovascular electrophysiology, 26(4), 363-370. (Read full article)
  33. Bunch TJ, May HT, Crandall BG, Weiss JP, Bair TL, Osborn JS, Anderson JL, Muhlestein JB, Lappe DL, Johnson DL, Day J (2013). Intracardiac ultrasound for esophageal anatomic assessment and localization during left atrial ablation for atrial fibrillation. Journal of cardiovascular electrophysiology, 24(1), 33-9. (Read full article)
  34. Malasana G, Day JD, Weiss JP, Crandall BG, Bair TL, May HT, Osborn JS, Anderson JL, Muhlestein JB, Lappe DL, Nelson J, Bunch T (2011). A strategy of rapid cardioversion minimizes the significance of early recurrent atrial tachyarrhythmias after ablation for atrial fibrillation. Journal of cardiovascular electrophysiology, 22(7), 761-6. (Read full article)
  35. Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS, Anderson JL, Muhlestein JB, Horne BD, Lappe DL, Day J (2011). Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. Journal of cardiovascular electrophysiology, 22(8), 839-45. (Read full article)
  36. Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS, Anderson JL, Lappe DL, Muhlestein JB, Nelson J, Allison S, Foley T, Anderson L, Day J (2009). Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures. Journal of cardiovascular electrophysiology, 20(9), 988-93. (Read full article)
  37. Smith MB, Christensen N, Wang S, Strohecker J, Day JD, Weiss JP, Crandall BG, Osborn JS, Anderson JL, Horne BD, Muhlestein JB, Lappe DL, Moss H, Oliver J, Viau K, Bunch T (2010). Warfarin knowledge in patients with atrial fibrillation: implications for safety, efficacy, and education strategies. Cardiology, 116(1), 61-9. (Read full article)
  38. Jacobs AK, Anderson JL, Halperin JL, ACC/AHA TASK FORCE MEMBERS., Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Fleisher LA, Gidding S, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Wijeysundera D (2014). The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation, 130(14), 1208-17. (Read full article)
  39. Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, Halperin JL, Hlatky MA, Jacobs AK, Mark DB, Masoudi FA, Peterson ED, Shaw LJ, ACC/AHA Task Force on Performance Measures., ACC/AHA Task Force on Practice Guidelines (2014). ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation, 129(22), 2329-45. (Read full article)
  40. Nallamothu BK, Tommaso CL, Anderson HV, Anderson JL, Cleveland JC Jr, Dudley RA, Duffy PL, Faxon DP, Gurm HS, Hamilton LA, Jensen NC, Josephson RA, Malenka DJ, Maniu CV, McCabe KW, Mortimer JD, Patel MR, Persell SD, Rumsfeld JS, Shunk KA, Smith SC Jr, Stanko SJ, Watts (2014). ACC/AHA/SCAI/AMA-Convened PCPI/NCQA 2013 Performance Measures for Adults Undergoing Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures, the Society for Cardiovascular Angiography and Interventions, the American Medical Association-Convened Physician Consortium for Performance Improvement, and the National Committee for Quality Assurance. Circulation, 129(8), 926-49. (Read full article)
  41. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Jneid H, Ettinger SM, Ganiats TG, Lincoff AM, Philippides GJ, Zidar JP, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2013). 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 127(23), e663-828. (Read full article)
  42. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, Robinson M, Barton S, Brunisholz K, Mower CP, Huntinghouse JA, Rollo JS, Siler D, Bair TL, Knight S, Muhlestein JB, Carlquist J (2012). A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation, 125(16), 1997-2005. (Read full article)
  43. 2012 Writing Committee Members., Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Anderson JL, American College of Cardiology Foundation., American Heart Association Task Force on Practice Guidelines (2012). 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 126(7), 875-910. (Read full article)
  44. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2009). 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 120(22), 2271-306. (Read full article)
  45. Gibbons RJ, Gardner TJ, Anderson JL, Goldstein LB, Meltzer N, Weintraub WS, Yancy CW, American Heart Association Advocacy Coordinating Committee (2009). The American Heart Association's principles for comparative effectiveness research: a policy statement from the American Heart Association. Circulation, 119(22), 2955-62. (Read full article)
  46. May HT, Anderson JL, Winegar DA, Rollo J, Connelly MA, Otvos JD, Muhlestein J (2016). Utility of high density lipoprotein particle concentration in predicting future major adverse cardiovascular events among patients undergoing angiography. Clinical biochemistry, 49(15), 1122-1126. (Read full article)
  47. Graves KG, Muhlestein JB, Lappé DL, McCubrey RO, May HT, Knight S, Le VT, Bair TL, Anderson JL, Horne B (2018). Practical laboratory-based clinical decision tools and associations with short-term bleeding and mortality outcomes. Clinica chimica acta; international journal of clinical chemistry, 482, 166-171. (Read full article)
  48. Lappé JM, Horne BD, Shah SH, May HT, Muhlestein JB, Lappé DL, Kfoury AG, Carlquist JF, Budge D, Alharethi R, Bair TL, Kraus WE, Anderson J (2011). Red cell distribution width, C-reactive protein, the complete blood count, and mortality in patients with coronary disease and a normal comparison population. Clinica chimica acta; international journal of clinical chemistry, 412(23-24), 2094-9. (Read full article)
  49. Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, Wadelius (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clinical pharmacology and therapeutics, 102(3), 397-404. (Read full article)
  50. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE, Altman RB, Clinical Pharmacogenetics Implementation Consortium (2011). Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clinical pharmacology and therapeutics, 90(4), 625-9. (Read full article)
  51. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Angchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, Lindh JD, Carlquist JF, Horne BD, Grice G, Milligan PE, Eby C, Shin J, Kim H, Kurnik D, Stein CM, McMillin G, Pendleton RC, Berg RL, Deloukas P, Gage B (2010). Integration of genetic, clinical, and INR data to refine warfarin dosing. Clinical pharmacology and therapeutics, 87(5), 572-8. (Read full article)
  52. Martin SS, Khokhar AA, May HT, Kulkarni KR, Blaha MJ, Joshi PH, Toth PP, Muhlestein JB, Anderson JL, Knight S, Li Y, Spertus JA, Jones SR, Lipoprotein Investigators Collaborative (LIC) (2015). HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. European heart journal, 36(1), 22-30. (Read full article)
  53. Horne BD, Muhlestein JB, Bennett ST, Muhlestein JB, Ronnow BS, May HT, Bair TL, Anderson J (2015). Association of the dispersion in red blood cell volume with mortality. European journal of clinical investigation, 45(6), 541-9. (Read full article)
  54. Arnett DK, Goodman RA, Halperin JL, Anderson JL, Parekh AK, Zoghbi W (2014). AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. Journal of the American College of Cardiology, 64(17), 1851-6. (Read full article)
  55. Jacobs AK, Anderson JL, Halperin J (2014). The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 64(13), 1373-84. (Read full article)
  56. Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, Halperin JL, Hlatky MA, Jacobs AK, Mark DB, Masoudi FA, Peterson ED, Shaw L (2014). ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Journal of the American College of Cardiology, 63(21), 2304-22. (Read full article)
  57. Mark DB, Anderson JL, Brinker JA, Brophy JA, Casey DE Jr, Cross RR, Edmundowicz D, Hachamovitch R, Hlatky MA, Jacobs JE, Jaskie S, Kett KG, Malhotra V, Masoudi FA, McConnell MV, Rubin GD, Shaw LJ, Sherman ME, Stanko S, Ward R (2014). ACC/AHA/ASE/ASNC/HRS/IAC/Mended Hearts/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SNMMI 2014 health policy statement on use of noninvasive cardiovascular imaging: a report of the American College of Cardiology Clinical Quality Committee. Journal of the American College of Cardiology, 63(7), 698-721. (Read full article)
  58. Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Le Heuzey JY, Kay GN, Olsson SB, Prystowsky EN, Tamargo JL, Wann (2013). Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 61(18), 1935-44. (Read full article)
  59. Holmes MV, Simon T, Exeter HJ, Folkersen L, Asselbergs FW, Guardiola M, Cooper JA, Palmen J, Hubacek JA, Carruthers KF, Horne BD, Brunisholz KD, Mega JL, van Iperen EPA, Li M, Leusink M, Trompet S, Verschuren JJW, Hovingh GK, Dehghan A, Nelson CP, Kotti S, Danchin N, Scholz M, Haase CL, Rothenbacher D, Swerdlow DI, Kuchenbaecker KB, Staines-Urias E, Goel A, van 't Hooft F, Gertow K, de Faire U, Panayiotou AG, Tremoli E, Baldassarre D, Veglia F, Holdt LM, Beutner F, Gansevoort RT, Navis GJ, Mateo Leach I, Breitling LP, Brenner H, Thiery J, Dallmeier D, Franco-Cereceda A, Boer JMA, Stephens JW, Hofker MH, Tedgui A, Hofman A, Uitterlinden AG, Adamkova V, Pitha J, Onland-Moret NC, Cramer MJ, Nathoe HM, Spiering W, Klungel OH, Kumari M, Whincup PH, Morrow DA, Braund PS, Hall AS, Olsson AG, Doevendans PA, Trip MD, Tobin MD, Hamsten A, Watkins H, Koenig W, Nicolaides AN, Teupser D, Day INM, Carlquist JF, Gaunt TR, Ford I, Sattar N, Tsimikas S, Schwartz GG, Lawlor DA, Morris RW, Sandhu MS, Poledne R, Maitland-van der Zee AH, Khaw KT, Keating BJ, van der Harst P, Price JF, Mehta SR, Yusuf S, Witteman JCM, Franco OH, Jukema JW, de Knijff P, Tybjaerg-Hansen A, Rader DJ, Farrall M, Samani NJ, Kivimaki M, Fox KAA, Humphries SE, Anderson JL, Boekholdt SM, Palmer TM, Eriksson P, Paré G, Hingorani AD, Sabatine MS, Mallat Z, Casas JP, Talmud P (2013). Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. Journal of the American College of Cardiology, 62(21), 1966-1976. (Read full article)
  60. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Jneid H, Ettinger SM, Ganiats TG, Philippides GJ, Jacobs AK, Halperin JL, Albert NM, Creager MA, DeMets D, Guyton RA, Kushner FG, Ohman EM, Stevenson W, Yancy C (2013). 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 61(23), e179-347. (Read full article)
  61. Chan K, Patel RS, Newcombe P, Nelson CP, Qasim A, Epstein SE, Burnett S, Vaccarino VL, Zafari AM, Shah SH, Anderson JL, Carlquist JF, Hartiala J, Allayee H, Hinohara K, Lee BS, Erl A, Ellis KL, Goel A, Schaefer AS, El Mokhtari NE, Goldstein BA, Hlatky MA, Go AS, Shen GQ, Gong Y, Pepine C, Laxton RC, Whittaker JC, Tang WH, Johnson JA, Wang QK, Assimes TL, Nöthlings U, Farrall M, Watkins H, Richards AM, Cameron VA, Muendlein A, Drexel H, Koch W, Park JE, Kimura A, Shen WF, Simpson IA, Hazen SL, Horne BD, Hauser ER, Quyyumi AA, Reilly MP, Samani NJ, Ye (2013). Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. Journal of the American College of Cardiology, 61(9), 957-70. (Read full article)
  62. Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE, Disesa VJ, Hiratzka LF, Hutter AM Jr, Jessen ME, Keeley EC, Lahey SJ, Lange RA, London MJ, Mack MJ, Patel MR, Puskas JD, Sabik JF, Selnes O, Shahian DM, Trost JC, Winniford MD, American College of Cardiology Foundation., American Heart Association Task Force on Practice Guidelines., American Association for Thoracic Surgery., Society of Cardiovascular Anesthesiologists., Society of Thoracic Surgeons (2011). 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. Journal of the American College of Cardiology, 58(24), e123-210. (Read full article)
  63. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright R (2011). 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal of the American College of Cardiology, 57(19), 1920-59. (Read full article)
  64. American College of Cardiology Foundation Appropriate Use Criteria Task Force., American Society of Echocardiography., American Heart Association., American Society of Nuclear Cardiology., Heart Failure Society of America., Heart Rhythm Society., Society for Cardiovascular Angiography and Interventions., Society of Critical Care Medicine., Society of Cardiovascular Computed Tomography., Society for Cardiovascular Magnetic Resonance., Douglas PS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, Picard MH, Polk DM, Ragosta M, Ward RP, Weiner R (2011). ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians. Journal of the American College of Cardiology, 57(9), 1126-66. (Read full article)
  65. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams D (2009). 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 54(23), 2205-41. (Read full article)
  66. Krumholz HM, Anderson JL, Bachelder BL, Fesmire FM, Fihn SD, Foody JM, Ho PM, Kosiborod MN, Masoudi FA, Nallamothu BK, American College of Cardiology/American Heart Association Task Force on Performance Measures., American Academy of Family Physicians., American College of Emergency Physicians., American Association of Cardiovascular and Pulmonary Rehabilitation., Society for Cardiovascular Angiography and Interventions., Society of Hospital Medicine (2008). ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American Academy of Family Physicians and American College of Emergency Physicians Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. Journal of the American College of Cardiology, 52(24), 2046-99. (Read full article)
  67. Barbagelata A, Bethea CF, Severance HW, Mentz RJ, Albert D, Barsness GW, Le VT, Anderson JL, Bunch TJ, Yanowitz F, Chisum B, Ronnow BS, Muhlestein J (2018). Smartphone ECG for evaluation of ST-segment elevation myocardial infarction (STEMI): Design of the ST LEUIS International Multicenter Study. Journal of electrocardiology, 51(2), 260-264. (Read full article)
  68. Muhlestein JB, Le V, Albert D, Moreno FL, Anderson JL, Yanowitz F, Vranian RB, Barsness GW, Bethea CF, Severance HW, Ramo B, Pierce J, Barbagelata A, Muhlestein J (2015). Smartphone ECG for evaluation of STEMI: results of the ST LEUIS Pilot Study. Journal of electrocardiology, 48(2), 249-59. (Read full article)
  69. Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, Fonarow GC, Lange RA, Levine GN, Maddox TM, Naidu SS, Ohman EM, Smith PK, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, American College of Cardiology/Americal Heart Association Task Force on Practice Guidelines., American Association for Thoracic Surgery., Preventive Cardiovascular Nurses Association., Society for Cardiovascular Angiography and Interventions., Society of Thoracic Surgeons (2015). 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. The Journal of thoracic and cardiovascular surgery, 149(3), e5-23. (Read full article)
  70. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Creager MA, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Stevenson WG, Yancy CW, American College of Cardiology., American College of Cardiology/American Heart Association., American Heart Association (2014). 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. The Journal of thoracic and cardiovascular surgery, 148(1), e1-e132. (Read full article)
  71. Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Anderson JL, Li J, Rodriguez T Jr, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple B, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dávila-Román V, Eby C (2019). Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial. JAMA, 322(9), 834-842. (Read full article)
  72. Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodríguez T Jr, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple BD, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dávila-Román V, Eby C (2017). Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial. JAMA, 318(12), 1115-1124. (Read full article)
  73. Muhlestein JB, Lappé DL, Lima JA, Rosen BD, May HT, Knight S, Bluemke DA, Towner SR, Le V, Bair TL, Vavere AL, Anderson J (2014). Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA, 312(21), 2234-43. (Read full article)
  74. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine M (2010). Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA, 304(16), 1821-30. (Read full article)
  75. FUTURA/OASIS-8 Trial Group., Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, López-Sendón JL, Budaj A, Diaz R, Avezum A, Widimsky P, Rao SV, Chrolavicius S, Meeks B, Joyner C, Pogue J, Yusuf (2010). Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA, 304(12), 1339-49. (Read full article)
  76. Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW, Thompson JR, Horne BD, Stewart AF, Assimes TL, Wild PS, Allayee H, Nitschke PL, Patel RS, Myocardial Infarction Genetics Consortium., Wellcome Trust Case Control Consortium., Martinelli N, Girelli D, Quyyumi AA, Anderson JL, Erdmann J, Hall AS, Schunkert H, Quertermous T, Blankenberg S, Hazen SL, Roberts R, Kathiresan S, Samani NJ, Epstein SE, Rader D (2011). Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet (London, England), 377(9763), 383-92. (Read full article)
  77. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S, CURRENT-OASIS 7 trial investigators (2010). Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet (London, England), 376(9748), 1233-43. (Read full article)
  78. Lp-PLA(2) Studies Collaboration., Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh (2010). Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (London, England), 375(9725), 1536-44. (Read full article)
  79. Brunner KJ, Bunch TJ, Mullin CM, May HT, Bair TL, Elliot DW, Anderson JL, Mahapatra (2014). Clinical predictors of risk for atrial fibrillation: implications for diagnosis and monitoring. Mayo Clinic proceedings, 89(11), 1498-505. (Read full article)
  80. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH, COAG Investigators (2013). A pharmacogenetic versus a clinical algorithm for warfarin dosing. The New England journal of medicine, 369(24), 2283-93. (Read full article)
  81. CURRENT-OASIS 7 Investigators., Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf (2010). Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. The New England journal of medicine, 363(10), 930-42. (Read full article)
  82. Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, Afzal R, Chrolavicius S, Jolly SS, Widimsky P, Avezum A, Rupprecht HJ, Zhu J, Col J, Natarajan MK, Horsman C, Fox KA, Yusuf S, TIMACS Investigators (2009). Early versus delayed invasive intervention in acute coronary syndromes. The New England journal of medicine, 360(21), 2165-75. (Read full article)
  83. International Warfarin Pharmacogenetics Consortium., Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson J (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. The New England journal of medicine, 360(8), 753-64. (Read full article)
  84. Rollo J, Knight S, May HT, Anderson JL, Muhlestein JB, Bunch TJ, Carlquist (2015). Incidence of dementia in relation to genetic variants at PITX2, ZFHX3, and ApoE ¿4 in atrial fibrillation patients. Pacing and clinical electrophysiology, 38(2), 171-7. (Read full article)
  85. Bunch TJ, Horne BD, Asirvatham SJ, Day JD, Crandall BG, Weiss JP, Osborn JS, Anderson JL, Muhlestein JB, Lappe DL, Pope CA 3r (2011). Atrial fibrillation hospitalization is not increased with short-term elevations in exposure to fine particulate air pollution. Pacing and clinical electrophysiology, 34(11), 1475-9. (Read full article)
  86. Bunch TJ, Mahapatra S, Murdock D, Molden J, Weiss JP, May HT, Bair TL, Mader KM, Crandall BG, Day JD, Osborn JS, Muhlestein JB, Lappe DL, Anderson J (2011). Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing and clinical electrophysiology, 34(12), 1600-6. (Read full article)
  87. Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, Anderson JL, Lappe DL, Muhlestein JB, Nelson J, Day J (2010). Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in octogenarians. Pacing and clinical electrophysiology, 33(2), 146-52. (Read full article)
  88. Crandall MA, Horne BD, Day JD, Anderson JL, Muhlestein JB, Crandall BG, Weiss JP, Osborne JS, Lappé DL, Bunch T (2009). Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors. Pacing and clinical electrophysiology, 32(8), 981-6. (Read full article)
  89. Kwan AC, May HT, Cater G, Sibley CT, Rosen BD, Lima JA, Rodriguez K, Lappe DL, Muhlestein JB, Anderson JL, Bluemke D (2014). Coronary artery plaque volume and obesity in patients with diabetes: the factor-64 study. Radiology, 272(3), 690-9. (Read full article)
  90. Horne BD, Hegewald M, Muhlestein JB, May HT, Huggins EJ, Bair TL, Anderson J (2015). Pulmonary-Specific Intermountain Risk Score Predicts All-Cause Mortality via Spirometry, the Red Cell Distribution Width, and Other Laboratory Parameters. Respiratory care, 60(9), 1314-23. (Read full article)
  91. Fung E, Patsopoulos NA, Belknap SM, O'Rourke DJ, Robb JF, Anderson JL, Shworak NW, Moore J (2012). Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Seminars in thrombosis and hemostasis, 38(8), 893-904. (Read full article)
  92. Belley-Cote EP, Hanif H, D'Aragon F, Eikelboom JW, Anderson JL, Borgman M, Jonas DE, Kimmel SE, Manolopoulos VG, Baranova E, Maitland-van der Zee AH, Pirmohamed M, Whitlock R (2015). Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis. Thrombosis and haemostasis, 114(4), 768-77. (Read full article)
  93. Carlquist JF, Knight S, Horne BD, Huntinghouse JA, Rollo JS, Muhlestein JB, May H, Anderson J (2013). Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. Thrombosis and haemostasis, 109(4), 744-54. (Read full article)
  94. Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, Pendleton RC, McMillin GA, Burmester JK, Kurnik D, Stein CM, Caldwell MD, Eby CS, Rane A, Lindh JD, Shin JG, Kim HS, Angchaisuksiri P, Glynn RJ, Kronquist KE, Carlquist JF, Grice GR, Barrack RL, Li J, Gage B (2012). Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thrombosis and haemostasis, 107(2), 232-40. (Read full article)
  95. May HT, Anderson JL, Muhlestein JB, Lappé DL, Ronnow BS, Horne B (2016). Improvement in the predictive ability of the Intermountain Mortality Risk Score by adding routinely collected laboratory tests such as albumin, bilirubin, and white cell differential count. Clinical chemistry and laboratory medicine, 54(10), 1619-28. (Read full article)
  96. Carlquist JF, Horne BD, Mower C, Park J, Huntinghouse J, McKinney JT, Muhlestein JB, Anderson J (2010). An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. Journal of thrombosis and thrombolysis, 30(3), 358-64. (Read full article)
  97. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra D (2010). A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. PharmacoEconomics, 28(1), 61-74. (Read full article)
  98. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Jacobs AK, Hochman JS, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO, American College of Cardiology Foundation., American Heart Association Task Force on Practice Guidelines (2009). 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Catheterization and cardiovascular interventions, 74(7), E25-68. (Read full article)
  99. Horne BD, Muhlestein JB, Lappé DL, May HT, Carlquist JF, Galenko O, Brunisholz KD, Anderson J (2013). Randomized cross-over trial of short-term water-only fasting: metabolic and cardiovascular consequences. Nutrition, metabolism, and cardiovascular diseases, 23(11), 1050-7. (Read full article)
  100. Horne BD, May HT, Kfoury AG, Renlund DG, Muhlestein JB, Lappé DL, Rasmusson KD, Bunch TJ, Carlquist JF, Bair TL, Jensen KR, Ronnow BS, Anderson J (2010). The Intermountain Risk Score (including the red cell distribution width) predicts heart failure and other morbidity endpoints. European journal of heart failure, 12(11), 1203-13. (Read full article)
  101. Anderson JL, May HT, Bair TL, Muhlestein JB, Horne BD, Carlquist J (2009). Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study. Journal of cardiovascular pharmacology and therapeutics, 14(3), 170-5. (Read full article)
  102. Do EJ, Lenzini P, Eby CS, Bass AR, McMillin GA, Stevens SM, Woller SC, Pendleton RC, Anderson JL, Proctor P, Nunley RM, Davila-Roman V, Gage B (2012). Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. The pharmacogenomics journal, 12(5), 417-24. (Read full article)
  103. May HT, Nelson JR, Kulkarni KR, Anderson JL, Horne BD, Bair TL, Muhlestein J (2013). A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL¿+IDL]). Lipids in health and disease, 12, 55. (Read full article)
  104. Gardner BI, Bingham SE, Allen MR, Blatter DD, Anderson J (2009). Cardiac magnetic resonance versus transthoracic echocardiography for the assessment of cardiac volumes and regional function after myocardial infarction: an intrasubject comparison using simultaneous intrasubject recordings. Cardiovascular ultrasound, 7, 38. (Read full article)
  105. Carlquist JF, Knight S, Cawthon RM, Le VT, Jared Bunch T, Horne BD, Rollo JS, Huntinghouse JA, Brent Muhlestein J, Anderson J (2016). Shortened telomere length is associated with paroxysmal atrial fibrillation among cardiovascular patients enrolled in the Intermountain Heart Collaborative Study. Heart rhythm, 13(1), 21-7. (Read full article)
  106. Jacobs V, May HT, Bair TL, Crandall BG, Cutler M, Day JD, Weiss JP, Osborn JS, Muhlestein JB, Anderson JL, Mallender C, Bunch T (2015). The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation. Heart rhythm, 12(4), 681-6. (Read full article)
  107. Sheldon SH, Bunch TJ, Cogert GA, Acker NG, Dalzell CM, Higgins JV, Espinosa RE, Asirvatham SJ, Cha YM, Felmlee JP, Watson RE Jr, Anderson JL, Brooks MH, Osborn JS, Friedman P (2015). Multicenter study of the safety and effects of magnetic resonance imaging in patients with coronary sinus left ventricular pacing leads. Heart rhythm, 12(2), 345-9. (Read full article)
  108. Jacobs V, Woller SC, Stevens S, May HT, Bair TL, Anderson JL, Crandall BG, Day JD, Johanning K, Long Y, Mallender C, Olson JL, Osborn JS, Weiss JP, Bunch T (2014). Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart rhythm, 11(12), 2206-13. (Read full article)
  109. Bunch TJ, May HT, Bair TL, Weiss JP, Crandall BG, Osborn JS, Mallender C, Anderson JL, Muhlestein BJ, Lappe DL, Day J (2013). Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart rhythm, 10(9), 1272-7. (Read full article)
  110. Bunch TJ, May HT, Bair TL, Johnson DL, Weiss JP, Crandall BG, Osborn JS, Anderson JL, Muhlestein JB, Lappe DL, Day J (2013). Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes. Heart rhythm, 10(9), 1257-62. (Read full article)
  111. Bunch TJ, May HT, Bair TL, Crandall BG, Weiss JP, Osborn JS, Anderson JL, Muhlestein JB, Horne BD, Lappe DL, Day J (2011). Trends in early and late mortality in patients undergoing coronary catheterization for myocardial infarction: implications on observation periods and risk factors to determine ICD candidacy. Heart rhythm, 8(9), 1460-6. (Read full article)
  112. Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, Anderson JL, Muhlestein JB, Horne BD, Lappe DL, Day J (2010). Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart rhythm, 7(4), 433-7. (Read full article)
  113. French B, Joo J, Geller NL, Kimmel SE, Rosenberg Y, Anderson JL, Gage BF, Johnson JA, Ellenberg JH, COAG (Clarification of Optimal Anticoagulation through Genetics) Investigators (2010). Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials, 11, 108. (Read full article)
  114. Carlquist JF, Moody DE, Knight S, Johnson EG, Fang WB, Huntinghouse JA, Rollo JS, Webster LR, Anderson J (2015). A Possible Mechanistic Link Between the CYP2C19 Genotype, the Methadone Metabolite Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidene (EDDP), and Methadone-Induced Corrected QT Interval Prolongation in a Pilot Study. Molecular diagnosis & therapy, 19(2), 131-8. (Read full article)
  115. Horne BD, Muhlestein JB, Lappé DL, Brunisholz KD, May HT, Kfoury AG, Carlquist JF, Alharethi R, Budge D, Whisenant BK, Bunch TJ, Ronnow BS, Rasmusson KD, Bair TL, Jensen KR, Anderson J (2011). The intermountain risk score predicts incremental age-specific long-term survival and life expectancy. Translational research, 158(5), 307-14. (Read full article)
  116. Horne BD, Lappé DL, Muhlestein JB, May HT, Ronnow BS, Brunisholz KD, Kfoury AG, Bunch TJ, Alharethi R, Budge D, Whisenant BK, Bair TL, Jensen KR, Anderson J (2013). Repeated measurement of the intermountain risk score enhances prognostication for mortality. PloS one, 8(7), e69160. (Read full article)
  117. May HT, Bair TL, Reiss-Brennan B, Knight S, Anderson JL, Horne BD, Brunisholz KD, Muhlestein J (2017). The association of antidepressant and statin use with death and incident cardiovascular disease varies by depression severity. Psychology, health & medicine, 22(8), 919-931. (Read full article)
  118. Muhlestein JB, Lappe DL, Anderson JL, Muhlestein JB, Budge D, May HT, Bennett ST, Bair TL, Horne B (2016). Both initial red cell distribution width (RDW) and change in RDW during heart failure hospitalization are associated with length of hospital stay and 30-day outcomes. International journal of laboratory hematology, 38(3), 328-37. (Read full article)
  119. Madsen TE, Pearson RR, Muhlestein JB, Lappé DL, Bair TL, Horne BD, Anderson JL, Intermountain Heart Collaborative (IHC) Study Group (2009). Risk of nephropathy is not increased by the administration of larger volume of contrast during coronary angiography. Critical pathways in cardiology, 8(4), 167-71. (Read full article)
  120. Robison CD, Bair TL, Horne BD, McCubrey RO, Lappe DL, Muhlestein JB, Anderson J (2014). Hypothyroidism as a risk factor for statin intolerance. Journal of clinical lipidology, 8(4), 401-7. (Read full article)
  121. Piccolo SR, Abo RP, Allen-Brady K, Camp NJ, Knight S, Anderson JL, Horne B (2009). Evaluation of genetic risk scores for lipid levels using genome-wide markers in the Framingham Heart Study. BMC proceedings, 3 Suppl 7, S46. (Read full article)
  122. Bunch TJ, May HT, Bair TL, Anderson JL, Crandall BG, Cutler MJ, Jacobs V, Mallender C, Muhlestein JB, Osborn JS, Weiss JP, Day J (2015). Long-Term Natural History of Adult Wolff-Parkinson-White Syndrome Patients Treated With and Without Catheter Ablation. Circulation. Arrhythmia and electrophysiology, 8(6), 1465-71. (Read full article)
  123. Horne BD, Rasmusson KD, Alharethi R, Budge D, Brunisholz KD, Metz T, Carlquist JF, Connolly JJ, Porter TF, Lappé DL, Muhlestein JB, Silver R, Stehlik J, Park JJ, May HT, Bair TL, Anderson JL, Renlund DG, Kfoury A (2011). Genome-wide significance and replication of the chromosome 12p11.22 locus near the PTHLH gene for peripartum cardiomyopathy. Circulation. Cardiovascular genetics, 4(4), 359-66. (Read full article)
  124. Horne BD, Carlquist JF, Muhlestein JB, Bair TL, Anderson J (2008). Association of variation in the chromosome 9p21 locus with myocardial infarction versus chronic coronary artery disease. Circulation. Cardiovascular genetics, 1(2), 85-92. (Read full article)
  125. Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, Krishnan V, Abraham WT, Lowes BD, Port JD, Davis GW, Lazzeroni LC, Robertson AD, Lavori PW, Liggett S (2010). An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circulation. Heart failure, 3(1), 21-8. (Read full article)
  126. Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, Taubert K, Smith SC J (2014). Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nature reviews. Cardiology, 11(10), 597-606. (Read full article)
  127. May HT, Nelson JR, Lirette ST, Kulkarni KR, Anderson JL, Griswold ME, Horne BD, Correa A, Muhlestein J (2016). The utility of the apolipoprotein A1 remnant ratio in predicting incidence coronary heart disease in a primary prevention cohort: The Jackson Heart Study. European journal of preventive cardiology, 23(7), 769-76. (Read full article)
  128. Horne BD, Anderson JL, Muhlestein JB, Ridker PM, Paynter N (2015). Complete blood count risk score and its components, including RDW, are associated with mortality in the JUPITER trial. European journal of preventive cardiology, 22(4), 519-26. (Read full article)
  129. Carlquist JF, McKinney JT, Horne BD, Camp NJ, Cannon-Albright L, Muhlestein JB, Hopkins P, Clarke JL, Mower CP, Park JJ, Nicholas ZP, Huntinghouse JA, Anderson J (2011). Common Variants in 6 Lipid-Related Genes Discovered by High-Resolution DNA Melting Analysis and Their Association with Plasma Lipids. Journal of clinical & experimental cardiology, 2(138), (Read full article)
  130. Pope CA, Muhlestein JB, Anderson JL, Cannon JB, Hales NM, Meredith KG, Le V, Horne B (2015). Short-Term Exposure to Fine Particulate Matter Air Pollution Is Preferentially Associated With the Risk of ST-Segment Elevation Acute Coronary Events. Journal of the American Heart Association, 4(12), (Read full article)

Conference Proceedings

  1. Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, Taubert K, Smith SC J (2014). World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCI. Global heart, 9(4), 457-67. (Read full article)

Letter

  1. Gurfinkel E, Bozovich G, Mautner B, Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne B, Lim (2000). Chlamydia pneumoniae in coronary artery disease. Circulation, 101(12), E118-9. (Read full article)